Profile of Pediatric Chronic Myeloid Leukemia in the Era of Imatinib: A Study from South India

Abstract

Introduction: Chronic myeloid leukemia (CML), a chronic hematologic malignancy, is rare in pediatric patients. Studies of the tyrosine kinase inhibitor imatinib are required so that uniform guidelines may focus on disease therapy and follow-up for children. We analyzed the clinicohematologic features of the disease, treatment response to imatinib, follow-up measures, and the impact of the disease on the patients and their family. Materials and Methods: All pediatric patients diagnosed with CML and treated and followed-up were studied regarding demographics, clinical features at presentation, and diagnostic profile, including laboratory parameters, peripheral blood smear test, fluorescent in situ hybridization and karyotyping, and reverse-transcriptase polymerase chain reaction for the BCR-ABL fusion gene. Treatment modalities, adverse reactions, remedial measures, assessment at every follow-up visit, patient’s education, parents’ socioeconomic status, and economic and psychological stresses were also evaluated. Results: Six patients were administered upfront therapy with a standard dose of imatinib. Hematological and biochemical parameters were monitored after the drug administration. We assessed the treatment response using molecular detection of the BCR-ABL transcripts. All patients who complied with drug therapy showed a complete molecular response and minimal toxic symptoms. However, parents found it difficult to cope socially and economically. Conclusion: Imatinib mesylate is effective and has a good molecular response, minimal toxicity, and good patient compliance. However, due to its cost, families reacquire financial debt, and the disease creates uncertainty about the child’s future, thereby necessitating psychosocioeconomic support for parents. Changes in the policies of cancer support groups are urgently needed to provide lifelong, lifesaving drugs free of cost.

Keywords

Chronic myeloid leukemia - imatinib - pediatric leukemia - socioeconomic impact

Publikationsverlauf

Artikel online veröffentlicht:
24. Mai 2021

• References

• 1 Raut LS. Chronic myeloid leukemia in children: A brief review. Clin Cancer Investing J 2014; 6: 467-71
• 2 Druker BJ, Sawyers CL, Capdeville R, Ford JM, Baccarani M, Goldman JM. et al. Chronic myelogenous leukemia. Hematology Am Soc Hematol Educ Program 2001; 2001: 87-112
• 3 Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F. et al. Evolving concepts in the management of chronic myeloid leukemia: Recommendations from an expert panel on behalf of the European leukemiaNet. Blood 2006; 108: 1809-20
• 4 Goldman JM. How I treat chronic myeloid leukemia in the imatinib era. Blood 2007; 110: 2828-37
• 5 Kumar N. Kuppuswamy’s socioeconomic status scale-updating for 2007. Indian J Pediatri 2007; 74: 1131-2
• 6 Han HR, Cho EJ, Kim D, Kim J. The report of coping strategies and psychosocial adjustment in Korean mothers of children with cancer. Psychooncology 2009; 18: 956-64
• 7 Röllig C, Ehninger G. How I treat hyperleukocytosis in acute myeloid leukemia. Blood 2015; 125: 3246-52
• 8 Champagne MA, Capdeville R, Krailo M, Qu W, Peng B, Rosamilia M. et al. Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: Results from a children’s oncology group phase 1 study. Blood 2004; 104: 2655-60
• 9 Millot F, Guilhot J, Nelken B, Leblanc T, De Bont ES, Békassy AN. et al. Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation. Leukemia 2006; 20: 187-92
• 10 Kolb EA, Pan Q, Ladanyi M, Steinherz PG. Imatinib mesylate in Philadelphia chromosome-positive leukemia of childhood. Cancer 2003; 98: 2643-50
• 11 Andolina JR, Neudorf SM, Corey SJ. How I treat childhood CML. Blood 2012; 119: 1821-30
• 12 Bansal S, Prabhash K, Parikh P. Chronic myeloid leukemia data from India. Indian J Med Paediatr Oncol 2013; 34: 154-8
• 13 Suttorp M. Innovative approaches of targeted therapy for CML of childhood in combination with paediatric haematopoietic SCT. Bone Marrow Transplant 2008; 42 (02) Suppl S40-6
• 14 Ray SS, Chakrabarti P, Nath U, Chaudhuri U. A single centre experience of treating CML in a tertiary care centre at Eastern India. 51st National Conference of Indian Society of Hematology and Transfusion Medicine 2010. 18th-21st November. 2010. Kolkata, India: Springer; 2010 129-81
• 15 Burke MJ. Profile of imatinib in pediatric leukemia. Pediatri Health Med Ther 2014; 5: 1-7
• 16 Vardiman JW. Chronic myelogenous leukemia, BCR-ABL1+. Am J Clin Pathol 2009; 132: 250-60
• 17 Cwynarski K, Roberts IA, Iacobelli S, van Biezen A, Brand R, Devergie A. et al. Stem cell transplantation for chronic myeloid leukemia in children. Blood 2003; 102: 1224-31
• 18 Raut LS. Chronic myeloid leukemia in children. A brief review. Clin Cancer Investig J 2014; 3: 467-71
• 19 Muramatsu H, Kojima S, Yoshimi A, Atsuta Y, Kato K, Nagatoshi Y. et al. Outcome of 125 children with chronic myelogenous leukemia who received transplants from unrelated donors: The Japan Marrow Donor Program. Biol Blood Marrow Transplant 2010; 16: 231-8
• 20 Millot F, Baruchel A, Guilhot J, Petit A, Leblanc T, Bertrand Y. et al. Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: Results of the French national phase IV trial. J Clin Oncol 2011; 29: 2827-32
• 21 Raut L, Bohara VV, Ray SS, Chakrabarti P, Chaudhuri U. Chronic myeloid leukemia in children and adolescents: A single center experience from Eastern India. South Asian J Cancer 2013; 2: 260-4
• 22 Linga VG, Ganta RR, Kalpathi KI, Gundeti S, Rajappa SJ, Digumarti R. et al. Response to imatinib mesylate in childhood chronic myeloid leukemia in chronic phase. South Asian J Cancer 2014; 3: 203-5
• 23 Ghadyalpatil N, Banawali S, Kurkure P, Arora B, Bansal S, Amare P. Efficacy and tolerability of imatinib mesylate in pediatric chronic myeloid leukemia in a large cohort: Results from a tertiary care referral centre in India. J Clin Oncol 2009; 27: 15s
• 24 Shima H, Tokuyama M, Tanizawa A, Tono C, Hamamoto K, Muramatsu H. et al. Distinct impact of imatinib on growth at prepubertal and pubertal ages of children with chronic myeloid leukemia. J Pediatr 2011; 159: 676-81
• 25 Ganesan P, Rajendranath R, Kandakumar V, Sagar TG. Treatment of chronic phase chronic myeloid leukemia with imatinib. Indian J Pediatr 2015; 82: 235-9
• 26 Rao GP, Malhotra S, Marwaha RK. Psychosocial study of leukemic children and their parents. Indian Pediatr 1992; 29: 985-90
• 27 Bayat M, Erdem E, Gül Kuzucu E. Depression, anxiety, hopelessness, and social support levels of the parents of children with cancer. J Pediatr Oncol Nurs 2008; 25: 247-53
• 28 Kohlsdorf M, Junior ALC. Psychosocial impact of pediatric cancer on parents: A literature review. Paideia 2012; 22: 119-29
• 29 Klassen AF, Klaassen R, Dix D, Pritchard S, Yanofsky R, O’Donnell M. et al. Impact of caring for a child with cancer on parents’ health-related quality of life. J Clin Oncol 2008; 26: 5884-9